InvestorsHub Logo
Followers 32
Posts 1683
Boards Moderated 0
Alias Born 01/11/2014

Re: raja48185 post# 305

Saturday, 12/10/2016 1:02:45 PM

Saturday, December 10, 2016 1:02:45 PM

Post# of 2139
yes.. the only issue is with % and market share... a potential $100-150B market, .. tenofir will easily get 20-30% of it... if so it would be $20B-$30B revenue , not $2B-$3B !
I think $2-$3B annual revenue for TAF and CMX157 is a reasonable estimate as long as HBV drugs remain as treatment (reducing virus load). When and if a (functional) cure will emerge (possibly with CRV431 combination with CMX157) then we will be talking about annual revenue in the tens of USD B, as it happens for HCV or even more than HCV
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HEPA News